Effect of Andrographolide on Monocyte Chemoattractant Protein-1 Expression at the Initiation Stage of Atherosclerosis in Atherogenic Diet-Fed Rats
Muhammad Yulis Hamidy1,2*
, Fadil Oenzil3, Yanwirasti4 and Yufri Aldi51Biomedical Programme, Faculty of Medicine, Andalas University, Padang, Indonesia.
2Department of Pharmacology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.
3Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia.
4Department of Anatomy, Faculty of Medicine, Andalas University, Padang, Indonesia.
5Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Andalas University, Padang, Indonesia.
Corresponding Author E-mail: yulis.hamidy@gmail.com
Abstract: To evaluate the effect of andrographolide on monocyte chemoattractant protein-1 (MCP-1) expression at the initiation stage of atherosclerosis in rats induced by an atherogenic diet. The research was conducted on 27 rats divided into 3 groups (n=9). Group 1 was given a standard diet. Group 2 was given an atherogenic diet of vitamin D3 700.000 IU/kg on the first day followed by 5% goat fat, 2% cholesterol, 0.2% cholic acid and standard diet up to 100% for 2 days to induce atherosclerosis initiation stage. Group 3 was given an atherogenic diet and treated with andrographolide 40 mg/kg. An immunohistochemical examination was performed to determine the expression of MCP-1. Data analysis using one-way Anova followed by post hoc test. The results showed the expression of MCP-1 in group 1 was 6.61 + 1.90, in group 2 was 32.99 + 3.74 and in group 3 was 9.61 + 2.47. There was a significant difference between group 3 treated with andrographolide 40 mg/kg compared with group 2 (p<0.001). There was no significant difference between group 3 treated with andrographolide 40 mg/kg and group 1 (p>0.05). In conclusion, andrographolide may inhibit MCP-1 expression at the initiation stage of atherosclerosis in the andrographolide treated rats. Thus, andrographolide could be a potential anti-atherosclerosis drug.
Keywords: Andrographolide; Atherosclerosis; MCP-1; Atherosclerosis Back to TOC